Market players such as
Sanofi, Rigel Pharmaceuticals, Kissei Pharmaceutical, Sobi, Shionogi & Co., Ltd., Amgen, Novartis, Zenyaku Kogyo, UCB Biopharma, Principia Biopharma, Baxalta, Takeda, Argenx, GC Pharma, Omeros Corporation, Biotest, Millennium Pharmaceuticals, Cellphire, Momenta Pharmaceuticals, ILTOO Pharma, Genosco, and several others are involved in developing Thrombocytopenia therapies.
Thrombocytopenia market might experience significant growth due to the expected launch of upcoming therapies such as
Rozanolixizumab (UCB7665); Rilzabrutinib (PRN-1008); BAX930; Efgartigimod (ARGX-113); Cablivi (caplacizumab); Tavalisse/Tavlesse (Fostamatinib); Doptelet (Avatrombopag); Nplate (Romiplostim); and Mulpleta (lusutrombopag), and others.
For additional information on Market Impact by Therapies, visit:
Thrombocytopenia is a condition in which the blood has a lower than a normal number of platelets. The condition can be inherited or acquired. Thrombocytopenia causes, somet
January 29, 2021 2:45pm EST Study has the potential to facilitate a filing for Emergency Use Authorization (EUA) SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 / / Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Fostamatinib is marketed in the U.S. as TAVALISSE
® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP).
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Fostamatinib is marketed in the U.S. as TAVALISSE
® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP). We are grateful to receive this funding from the DOD and for their demonstrated commitment towards finding safe and effective treatments for COVID-19 patients, said Raul Rodriguez, Rigel s president and CEO. These additional resources will contribute significantly to the advancement of our Phase 3 trial. D